Agents for inhibiting proliferation of obinutuzumab-resistant CD20-positive cancer cells, and pharmaceutical compositions, medicines, manufacture, methods for inhibiting proliferation of cells, methods of treatment, type II anti-CD20 antibodies, compounds, and combinations thereof, enhancers, and inducers related thereto
Combining type II anti-CD20 antibodies with chemotherapy agents like prednisolone and doxorubicin enhances treatment efficacy against obinutuzumab-resistant CD20-positive cancers, particularly B-cell non-Hodgkin's lymphoma, by inducing cell cycle arrest and cell death.
JP7590334B2Active Publication Date: 2024-11-26CHUGAI PHARMA CO LTD
Patent Information
- Application Number
- JP2021550624
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-04
- Filing Date
- 2020-09-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-09-18
Smart Images

Figure 0007590334000004 
Figure 0007590334000005 
Figure 0007590334000006
Abstract
Among CD20-positive cancers, some develop a resistance to obinutuzumab and some reappear after being treated with the use of obinutuzumab. According to the present invention, against a CD20-positive cancer resistant to obinutuzumab or a CD20-positive cancer reappearing after being treated with the use of obinutuzumab, a type II anti-CD20 antibody is used together with at least one compound selected from the group consisting of prednisolone, doxorubicin, vincristine, salts thereof and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, salts thereof and prodrugs thereof may be selected. Among these compounds, moreover, prednisolone, salts thereof and prodrugs thereof may be selected.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Use of type II anti-CD20 antibodies with increased antibody-dependent cytotoxic activity (ADCC) in combination with cyclophosphamide, vincristine, and doxorubicin for the treatment of non-Hodgkin lymphoma.
JP2011515428A
A pharmaceutical composition
WO2019017499A2
